Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

5.77
+0.13002.30%
Post-market: 5.780.0099+0.17%19:59 EDT
Volume:14.88M
Turnover:85.10M
Market Cap:2.51B
PE:-3.20
High:5.84
Open:5.64
Low:5.52
Close:5.64
52wk High:12.36
52wk Low:3.79
Shares:434.66M
Float Shares:415.00M
Volume Ratio:0.86
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8042
EPS(LYR):-1.6909
ROE:-86.34%
ROA:-39.08%
PB:2.73
PE(LYR):-3.41

Loading ...

Largest borrow rate increases among liquid names

TIPRANKS
·
Aug 15

Christopher Gibson, CEO, Reports Disposal of Recursion Pharmaceuticals Inc. Common Shares

Reuters
·
Aug 14

Nvidia-Linked Shares Rally. SoundHound AI up 21%; Nebius, CoreWeave up 7%

Tiger Newspress
·
Aug 08

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

TIPRANKS
·
Aug 06

Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating

TIPRANKS
·
Aug 06

Why Recursion Pharmaceuticals Stock Tanked on Tuesday

Motley Fool
·
Aug 06

Recursion (RXRX) Q2 Revenue Jumps 33%

Motley Fool
·
Aug 06

Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating

TIPRANKS
·
Aug 06

Stock Track | Recursion Pharmaceuticals Plummets 5% as Q2 Losses Widen Despite Revenue Beat

Stock Track
·
Aug 05

Stock Track | Recursion Pharmaceuticals Plummets 5% After Q2 Earnings Miss and Widened Losses

Stock Track
·
Aug 05

Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises

MT Newswires Live
·
Aug 05

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Net Loss $0.41 a Share, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
Aug 05

Recursion Pharmaceuticals reports Q2 EPS (41c), consensus (35c)

TIPRANKS
·
Aug 05

Stock Track | Recursion Pharmaceuticals Soars 7.93% Pre-Market on Q2 Revenue Beat and Clinical Trial Progress

Stock Track
·
Aug 05

Recursion's Cash Position As Of June 30, 2025 Was $533.8M, Expected To Extend Cash Runway Into The Fourth Quarter Of 2027

Benzinga
·
Aug 05

Recursion Pharmaceuticals Q2 2025 EPS $(0.41) Misses $(0.34) Estimate, Sales $19.223M Beat $16.233M Estimate

Benzinga
·
Aug 05

Recursion Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Reuters
·
Aug 05

Recursion Pharmaceuticals Q2 Operating Revenue USD 19.103 Million VS. Ibes Estimate USD 15.4 Million

THOMSON REUTERS
·
Aug 05

Recursion Pharmaceuticals Q2 EPS USD -0.41

THOMSON REUTERS
·
Aug 05

Nvidia-Linked Shares Rally. APLD up 9%; Nano-X Imaging, Serve Robotics up 5%; Nebius up 4%

Tiger Newspress
·
Aug 04